SCHEDULE 13G/A: BlackRock Reduces Stake in Lyell Immunopharma Below 5%

BlackRock, Inc. has filed an amended Schedule 13G indicating its beneficial ownership in Lyell Immunopharma, Inc. has decreased to 4.5% as of December 31, 2024.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its ownership in Lyell Immunopharma, Inc.
• As of December 31, 2024, BlackRock, Inc. beneficially owned 13,265,869 shares of Lyell Immunopharma's Common Stock.
• This represents 4.5% of the class of securities, indicating a reduction from a previous holding that was likely above 5%.
• BlackRock, Inc. holds sole voting power over 13,038,255 shares and sole dispositive power over 13,265,869 shares.
• No shared voting or dispositive power was reported.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual ownership disclosure and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.

Industry Context

This filing is a routine disclosure of institutional ownership changes. It does not provide specific insights into Lyell Immunopharma's operational performance or industry trends, but rather reflects a shift in a major investor's stake.

Stakeholder Impact

• Shareholders: BlackRock's reduction in stake below 5% may be interpreted by some shareholders as a change in investment sentiment, potentially influencing market perception of Lyell Immunopharma.

Key Dates

Keywords

Lyell Immunopharma, BlackRock, Schedule 13G, Common Stock, Institutional Ownership, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals